Matching articles for "Rykindo"
Drugs for Bipolar Disorder
The Medical Letter on Drugs and Therapeutics • April 1, 2024; (Issue 1699)
Bipolar disorder is characterized by episodes of
mania, hypomania, and depression. Recurrences of
manic or (more frequently) depressive symptoms
are common. About 15-20% of patients with bipolar
disorder...
Bipolar disorder is characterized by episodes of
mania, hypomania, and depression. Recurrences of
manic or (more frequently) depressive symptoms
are common. About 15-20% of patients with bipolar
disorder die by suicide.
In Brief: Three New Injectable Antipsychotic Drugs
The Medical Letter on Drugs and Therapeutics • December 25, 2023; (Issue 1692)
Three extended-release injectable formulations of
second-generation antipsychotic drugs — two of
risperidone (Rykindo, Uzedy) and one of aripiprazole
(Abilify Asimtufii) — have been approved by the...
Three extended-release injectable formulations of
second-generation antipsychotic drugs — two of
risperidone (Rykindo, Uzedy) and one of aripiprazole
(Abilify Asimtufii) — have been approved by the FDA
for treatment of schizophrenia in adults. Rykindo and
Abilify Asimtufii are also approved for maintenance
treatment of bipolar I disorder in adults. Other
extended-release injectable formulations of
risperidone and aripiprazole have been available in
the US for years (see Table 1).